Hans T. Chung

Dopamine D2 Receptor Dimers and Receptor-Blocking Peptides

Gordon Ng, Brian F. O’Dowd, Samuel P. Lee et al. · Biochemical and Biophysical Research Communications · 1996 · 266 citations

Functional Selectivity, Medicine, Neuropeptide Receptor +5

Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy

Gerard Morton, Merrylee McGuffin, Hans T. Chung et al. · Radiotherapy and Oncology · 2020 · 127 citations

Urology, Radiation Therapy, Medicine +5

Does Image-Guided Radiotherapy Improve Toxicity Profile in Whole Pelvic-Treated High-Risk Prostate Cancer? Comparison Between IG-IMRT and IMRT

Hans T. Chung, Ping Xia, Linda W. Chan et al. · International Journal of Radiation Oncology*Biology*Physics · 2008 · 122 citations

Adaptive Radiotherapy, Medical Imaging, Radiation Therapy +9

Can All Centers Plan Intensity-Modulated Radiotherapy (IMRT) Effectively? An External Audit of Dosimetric Comparisons Between Three-Dimensional Conformal Radiotherapy and IMRT for Adjuvant Chemoradiation for Gastric Cancer

Hans T. Chung, Brian Lee, Eileen Park et al. · International Journal of Radiation Oncology*Biology*Physics · 2008 · 109 citations

Adaptive Radiotherapy, Radiation Therapy, Medicine +11

Is single fraction 15Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?

Gerard Morton, Andrew Loblaw, Patrick Cheung et al. · Radiotherapy and Oncology · 2011 · 94 citations

Single Fraction 15Gy, Urology, Radiation Therapy +4